Evommune, a California biotech startup, has secured $115 million in Series C funding to advance its immune drug candidates, EVO756 and EVO301, targeting chronic immune conditions. The funding will support three Phase 2 trials, with results expected by the end of 2026. EVO756, an oral treatment for chronic skin hives, aims to be a first-in-class therapy, while EVO301 targets atopic dermatitis and shows promise in early testing.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
